Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9908786 | Lung Cancer | 2005 | 20 Pages |
Abstract
Recommendations: (i) paclitaxel or docetaxel combined with cisplatin is recommended as one of a number of chemotherapy options for the first-line treatment of advanced non-small cell lung cancer in patients with a good performance status; (ii) carboplatin may be combined with a taxane if a patient is unable or unwilling to take cisplatin; (iii) a taxane-gemcitabine combination may be considered for patients with a contraindication to cisplatin and carboplatin; (iv) no firm recommendation can be made on the optimal dose and schedule of taxane-based chemotherapy; however, commonly used regimens include cisplatin 75Â mg/m2 combined with either docetaxel 75Â mg/m2 or paclitaxel 135Â mg/m2 (24-h infusion) and carboplatin AUC 6 combined with paclitaxel 225Â mg/m2 (3-h infusion); (v) a single-agent taxane may be used if combination chemotherapy is considered inappropriate.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Quincy Chu, Mark Vincent, Diane Logan, Jean A. Mackay, William K. Evans, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care,